Sanofi Consumer Q3 FY26 Results (NSE: SANOFICONR)
Signal: Margin expansion
The read
The trajectory remains constructive: revenue growth accelerated to 12% YoY from 7% in the prior results series, domestic sales grew 19% on relaunch, volume expansion and market-share gains, and gross margin expanded 194bps YoY to 75.5% for the third consecutive quarter; PAT rose 22% to ₹766 million without an exceptional-item boost.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹263.1 Cr | +12% | +12% |
| Net profit | ₹76.6 Cr | +22% | |
| EPS | ₹33.26 | +22% | |
| EBIT margin | 38.7% |
P&L walk
Standalone revenue of ₹2,631 million grew 12% YoY and 12% QoQ, while EBITDA margin expanded to 38.7% from 36.3% as gross margin improved and profit before tax rose 22% to ₹1,027 million.
Key positives
- Revenue reached ₹2,631 million, up 12% YoY and 12% QoQ, with domestic sales growing 19% and management citing volume expansion and market-share gains.
- Gross margin expanded 194bps YoY to 75.5%, with raw-material cost stable at 15.5% of revenue versus 15.6% YoY; this is the third consecutive quarter of margin expansion in the prior results series.
- EBITDA margin improved 240bps YoY to 38.7%, while profit before tax rose 22% to ₹1,027 million.
- EPS rose 22% to ₹33.26, tracking the 22% increase in PAT to ₹766 million.
Key concerns
- Nine-month comparability remains affected by the 2024 product recall and staggered relaunches of Combiflam Suspension, Allegra Suspension and Depura Kids, as disclosed by the company.
- Gross margin declined 60bps sequentially from the implied 76.1% in the immediately preceding quarter, despite remaining higher YoY.
Research and educational content only. Not investment advice.